Intravesical BCG immunotherapy: adverse effects and management strategies
https://doi.org/10.21886/2308-6424-2026-14-1-131-138
Abstract
In accordance with contemporary clinical guidelines, intravesical BCG immunotherapy is indicated for patients with intermediate‑ and high‑risk non‑muscle‑invasive bladder cancer (NMIBC). Nonetheless, its use is constrained by a considerable burden of adverse events, notably urogenital tuberculosis. This study therefore sought to synthesise current evidence on the most observed complications of intravesical BCG therapy, approaches to reducing treatment‑related toxicity, and structured algorithms for the management of BCG‑associated adverse events.
Supporting agencies: The study was not sponsored.
About the Authors
M. P. Korchagin
Blokhin National Medical Research Centre for Oncology
Russian Federation
Competing Interests:
Russian Federation
Korchagin M. Pavlovich
Moscow
Competing Interests:
The authors declare no conflict of interest
Iu. A. Li
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
Iuliia A. Li
Moscow
Competing Interests:
The authors declare no conflict of interest
A. M. Dymov
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
Alim M. Dymov — Dr.Sc.(Med), Full Prof.
Moscow
Competing Interests:
The authors declare no conflict of interest
References
1. Kaprin A.D., Starinsky V.V., Shakhzadova A.O., eds. State of Cancer Care in Russia in 2024. Moscow: P.A. Herzen Moscow Oncology Research Institute – Branch of the National Medical Research Centre for Radiology of the Ministry of Health of the Russian Federation; 2025. (In Russian).
2. Lu JL, Xia QD, Lu YH, Liu Z, Zhou P, Hu HL, Wang SG. Efficacy of intravesical therapies on the prevention of recurrence and progression of non-muscle-invasive bladder cancer: A systematic review and network meta-analysis. Cancer Med. 2020;9(21):7800-7809. Erratum in: Cancer Med. 2021;10(16):5722. DOI: 10.1002/cam4.3513
3. Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus calmetteguerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol. 2005;174(1):86-91; discussion 91-2. DOI: 10.1097/01.ju.0000162059.64886.1c
4. Dymov A.M., Lee Y.A., Korchagin M.P., Dzharimok A.R., Vinarov A.Z., Gazimiev M.A. BCG-therapy for non-muscle-invasive bladder cancer: overview of the current trends. Urologiia. 2024;(2):116-120. (In Russian). DOI: 10.18565/urology.2024.2.116-120
5. Green DB, Kawashima A, Menias CO, Tanaka T, Redelman-Sidi G, Bhalla S, Shah R, King BF. Complications of Intravesical BCG Immunotherapy for Bladder Cancer. Radiographics. 2019;39(1):80-94. DOI: 10.1148/rg.2019180014
6. Griffin JG, Holzbeierlein J. Side effects of perioperative intravesical treatment and treatment strategies for these side effects. Urol Clin North Am. 2013;40(2):197-210. DOI: 10.1016/j.ucl.2013.01.005
7. Cabas P, Rizzo M, Giuffrè M, Antonello RM, Trombetta C, Luzzati R, Liguori G, Di Bella S. BCG infection (BCGitis) following intravesical instillation for bladder cancer and time interval between treatment and presentation: A systematic review. Urol Oncol. 2021;39(2):85-92. DOI: 10.1016/j.urolonc.2020.11.037
8. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124-1129. PMID: 10737480
9. Wan der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV; EORTC Genito-Urinary Tract Cancer Group. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol. 2003;44(4):429-434. DOI: 10.1016/s0302-2838(03)00357-9
10. Thyavihally YB, Dev P, Waigankar S, Pednekar A, Athikari N, Raut A, Khandekar A, Badlani N, Asari A. Intravesical bacillus Calmette-Guerin (BCG) in treating non-muscle invasive bladder cancer-analysis of adverse effects and effectiveness of two strains of BCG (Danish 1331 and Moscow-I). Asian J Urol. 2022;9(2):157-164. DOI: 10.1016/j.ajur.2021.05.002
11. Vilares AT, Nunes Silva C, Correia da Silva M, Sousa J, Viamonte B, Madureira AJ. Multisystemic BCGitis: A rare complication of intravesical BCG immunotherapy for bladder cancer. Radiol Case Rep. 2022;17(7):2383- 2387. DOI: 10.1016/j.radcr.2022.04.022
12. Pérez-Jacoiste Asín MA, Fernández-Ruiz M, López-Medrano F, Lumbreras C, Tejido Á, San Juan R, Arrebola-Pajares A, Lizasoain M, Prieto S, Aguado JM. Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine (Baltimore). 2014;93(17):236-254. DOI: 10.1097/MD.0000000000000119
13. Holmes BJ, larue RW, Black JH 3rd, Dionne K, Parrish NM, Melia MT. Mycotic aortic aneurysm due to intravesical BCG immunotherapy: Clinical manifestations and diagnostic challenges. Int J Mycobacteriol. 2014;3(1):60-65. DOI: 10.1016/j.ijmyco.2013.11.002
14. Choi SY, Ha MS, Kim JH, Chi BH, Kim JW, Chang IH, Kim TH, Myung SC. Low-dose versus standard-dose bacille Calmette-Guérin for non-muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized controlled trials. Investig Clin Urol. 2022;63(2):140-150. DOI: 10.4111/icu.20210340
15. Jasmer RM, McCowin MJ, Webb WR. Miliary lung disease after intravesical bacillus Calmette-Guérin immunotherapy. Radiology. 1996;201(1):43-44. DOI: 10.1148/radiology.201.1.8816518
16. Anis O, Yogev D, Dotan A, Tsur AM, David P, Vishnevskia Dai V, Laufer M, Dotan Z, Shoenfeld Y. Autoimmune disorders caused by intravesical bacillus Calmette-Guerine treatment: A systematic review. Autoimmun Rev. 2023;22(6):103329. DOI: 10.1016/j.autrev.2023.103329
17. Bassi P, Spinadin R, Carando R, Balta G, Pagano F. Modified induction course: a solution to side-effects? Eur Urol. 2000;37 Suppl 1:31-32. DOI: 10.1159/000052380
18. Nagai T, Okamura T, Tanaka Y, Moritoki Y, Kobayashi D, Kobayashi T, Akita H, Yasui T. Evaluation of the Dwell-Time and Dose Difference in Intravesical Bacillus Calmette-Guèrin Therapy. Asian Pac J Cancer Prev. 2019;20(5):1389-1392. DOI: 10.31557/APJCP.2019.20.5.1389
19. Andius P, Fehrling M, Holmäng S. Intravesical bacillus Calmette-Guèrin therapy: experience with a reduced dwell-time in patients with pronounced side-effects. BJU Int. 2005;96(9):1290-1293. DOI: 10.1111/j.1464-410X.2005.05817.x
20. Colombel M, Saint F, Chopin D, Malavaud B, Nicolas L, Rischmann P. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol. 2006;176(3):935-939. DOI: 10.1016/j.juro.2006.04.104
21. Pak S, Kim SY, Kim SH, Joung JY, Park WS, Chung J, Lee KH, Seo HK. Association Between Antibiotic Treatment and the Efficacy of Intravesical BCG Therapy in Patients With High-Risk Non-Muscle Invasive Bladder Cancer. Front Oncol. 2021;11:570077. DOI: 10.3389/fonc.2021.570077
22. Rodríguez Faba Ó, Fernández Gómez JM, Guerrero-Ramos F, ÁlvarezMaestro M, Ledo Cepero MJ, Unda Urzaiz M, Martínez-Piñeiro L, Cózar Olmo JM, Redorta JP, Álvarez-Ossorio JL. Consensus document on the implications of standardization of BCG supply in the management of patients with non-muscle-invasive bladder cancer. Actas Urol Esp (Engl Ed). 2024;48(10):718-731. (In English, Spanish). DOI: 10.1016/j.acuroe.2024.09.005
Review
For citations:
Korchagin M.P., Li I.A., Dymov A.M. Intravesical BCG immunotherapy: adverse effects and management strategies. Urology Herald. 2026;14(1):131-138. (In Russ.) https://doi.org/10.21886/2308-6424-2026-14-1-131-138
Views:
2689
JATS XML
Email this article 